BCL9L Antibody | Rockland Immunochemicals 600-401-Z46 product information

product summary

company name :

Rockland Immunochemicals

product type :

antibody

product name :

BCL9L Antibody

catalog :

600-401-Z46

quantity :

100 µg

clonality :

polyclonal

host :

domestic rabbit

conjugate :

nonconjugated

reactivity :

human, mouse, rat

application :

western blot, ELISA

more info or order :

Rockland Immunochemicals product webpage

product information

Catalog Number :

600-401-Z46

Name :

Anti-BCL9L (RABBIT) Antibody - 600-401-Z46

Display Name :

BCL9L Antibody

Application Note :

Anti-Bcl9L Antibody has been tested for use in ELISA, Western Blotting, Immunocytochemistry. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 157 kDa in Western Blots of specific cell lysates and tissues.

Buffer :

0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2

Clonality :

Polyclonal

Concentration Value :

1 mg/mL

Concentration Definition :

by UV absorbance at 280 nm

Conjugation :

(None)

Size :

100 µg

Default Unit :

µg

ELISA Dilution :

1:10,000

Western Blot Dilution :

1 µg/mL

Expiration :

Expiration date is one (1) year from date of opening.

Format :

IgG

Gene Name :

BCL9L

Host Animal :

Rabbit

General Disclaimer Note :

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

Immunogen :

Anti-Bcl9L antibody was prepared from whole rabbit serum produced by repeated immunizations with a 20 amino acid synthetic peptide near the N-terminus of human Bcl9L.

Packing Type :

Dry Ice

Physical State :

Liquid (sterile filtered)

Preservative :

0.02% (w/v) Sodium Azide

Purity and Specificity :

Anti-Bcl9L Antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography. Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.

Species Reactivity :

Human, mouse, rat

Storage :

Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Synonyms :

Bcl9L Antibody, BCL9-2, DLNB11, Protein BCL9-2, B-cell lymphoma 9-like protein

Target Species :

Human

Background :

Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

Immunogen Type :

Peptide

Low Endotoxin :

Sample Size :

Target Domain of Reactivity :

N-Terminus

Application Text :

ELISA,Western Blot,

Other :

Immunocytochemistry: 10 µg/mL

Category :

Primary Antibodies

Conjugation Name :

Unconjugated

UniProt :

Q86UU0

NCBI :

NP_872363

more info or order :

Rockland Immunochemicals product webpage